KOL Identification

A top-10 diagnostics company wanted to gauge preparedness and reactions to implementation of IVDR, and how that would impact a potential new product

An early-stage venture firm requested a high-level commercial due diligence of a potential investment

A diagnostic company wanted to assess the current and expected future landscapes for biopharma oncology genomics research and Dx / CDx

A large life science tools provider was interested in characterizing the genome engineering and engineered cell line market to identify potential opportunities to participate in the space

A leading diagnostics player wanted an assessment of the current and future carrier screening landscape, primarily in the U.S., to guide their product development strategy

A major diagnostics manufacturer had developed a novel technology for the rapid detection of infectious pathogens and required assistance in developing commercialization strategy and sales tactics. DeciBio’s services were contracted to profile relevant stakeholders, characterize existing workflows and acquisition / implementation processes, and develop a product-specific launch strategy.